NexImmune, Inc. (NEXI)
Largest Insider Buys in Sector
NEXI Stock Price History Chart
NEXI Stock Performance
About NexImmune, Inc.
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that …
Insider Activity of NexImmune, Inc.
Over the last 12 months, insiders at NexImmune, Inc. have bought $0 and sold $0 worth of NexImmune, Inc. stock.
On average, over the past 5 years, insiders at NexImmune, Inc. have bought $1.35M and sold $16,045 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1 shares for transaction amount of $0 was made by Jones Kristi (President and CEO) on 2024‑06‑11.
List of Insider Buy and Sell Transactions, NexImmune, Inc.
| 2024-06-11 | President and CEO | 1 – | $0.01 | $0 | -87.20% | |||
| 2023-11-22 | Sale | director | 3,992 0.3799% | $1.94 | $7,758 | +50.52% | ||
| 2023-11-21 | Sale | director | 3,833 0.382% | $2.16 | $8,287 | +40.98% | ||
| 2023-03-30 | director | 400,000 1.6133% | $0.41 | $164,120 | -33.95% | |||
| 2022-11-17 | director | 75,000 0.3304% | $0.48 | $35,918 | -31.42% | |||
| 2022-11-16 | director | 125,000 0.4914% | $0.48 | $60,300 | -39.22% | |||
| 2022-06-03 | 25,000 0.1084% | $2.14 | $53,538 | -78.24% | ||||
| 2022-05-31 | 39,280 0.1647% | $2.19 | $85,894 | -79.21% | ||||
| 2022-05-31 | 40,200 0.1836% | $2.38 | $95,760 | -79.21% | ||||
| 2022-03-29 | President and CEO | 10,000 0.0465% | $3.74 | $37,400 | -80.11% | |||
| 2022-03-24 | 131,622 0.6896% | $4.14 | $544,915 | -79.65% | ||||
| 2022-03-23 | 10,000 0.0442% | $2.67 | $26,653 | -73.33% | ||||
| 2022-03-22 | 30,000 0.1195% | $2.41 | $72,300 | -73.33% | ||||
| 2022-03-21 | 30,000 0.1362% | $2.14 | $64,080 | -65.05% | ||||
| 2022-03-18 | 30,000 0.1276% | $2.11 | $63,210 | -65.94% | ||||
| 2021-02-17 | director | 60,000 0.3342% | $17.00 | $1.02M | -42.01% | |||
| 2021-02-17 | director | 175,000 0.9747% | $17.00 | $2.98M | -42.01% | |||
| 2021-02-17 | Chief Operating Officer | 911 0.0051% | $17.00 | $15,487 | -42.01% | |||
| 2021-02-17 | Executive VP of Research & Dev | 5,882 0.0328% | $17.00 | $99,994 | -42.01% |
Insider Historical Profitability
| Jones Kristi | President and CEO | 1 0.0001% | $0.28 | 3 | 0 | <0.0001% |
| BARER SOL J | director | 2217814 159.0207% | $0.28 | 9 | 0 | <0.0001% |
| Verstandig Grant | 1078619 77.3386% | $0.28 | 4 | 0 | <0.0001% | |
| ZELDIS JEROME B | Executive VP of Research & Dev | 5882 0.4217% | $0.28 | 1 | 0 | <0.0001% |